Zum Hauptinhalt springen
xMedica

NCT07685808ClinicalTrials.gov

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A Phase 2, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, With Different Doses and Drug-Titration Algorithms in Participants Living With Overweight or Obesity

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing…

Phase 2360 Teilnehmende gesucht22 Studienzentren1 Land

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-07-06; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 264 other studies in this databaseCounted from the lead sponsor named in the record (Regeneron Pharmaceuticals)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 360 participants (target), run at 22 sites.

How this score is built
  • Enrolment25/40

    360 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration6/10

    Planned over about 18 months

  • Sponsor scale9/10

    Regeneron Pharmaceuticals has led 250 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well

Erkrankungen

  • Overweight or Obesity

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Key Inclusion Criteria: 1. Body Mass Index (BMI) ≥30.0 kg/m\^2 to \<45.0 kg/m\^2 at screening OR 2. BMI ≥27.0 kg/m\^2 at screening with at least 1 of the following weight-related co-morbidities: Hypertension, Dyslipidemia, Prediabetes, established Obstructive Sleep Apnea (OSA), established Coronary Artery Disease (CAD), Heart failure, established cerebrovascular disease as described in the protocol Key Exclusion Criteria: 1. Previous or current diagnosis of Type 1 or Type 2 diabetes at screening 2. Change in body weight \>5 kg within approximately 3 months before screening as described in the protocol 3. Bariatric surgery, including any procedures to revise, reverse, or remove any previous bariatric surgery interventions as described in the protocol 4. History of acute or chronic pancreatitis, cholecystitis, or symptomatic gallbladder stones 5. History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 2
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme360 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Regeneron Pharmaceuticals Sponsor

Studienarme und Interventionen

  • Olatorepatide arm 1EXPERIMENTAL
  • Olatorepatide arm 2EXPERIMENTAL
  • Olatorepatide arm 3EXPERIMENTAL
  • Olatorepatide arm 4EXPERIMENTAL
  • Olatorepatide arm 5EXPERIMENTAL
  • Matching Placebo arm 6ACTIVE_COMPARATOR

Interventionen

  • Arzneimittel Olatorepatide

    Administered per the protocol

  • Arzneimittel Placebo

    Administered per the protocol

Endpunkte

  1. Primärer Endpunkt

    Occurrence of Treatment-Emergent Adverse Events (TEAEs)

    Zeitrahmen Up to approximately 60 weeks

  2. Primärer Endpunkt

    Severity of TEAEs

    Zeitrahmen Up to approximately 60 weeks

  3. Primärer Endpunkt

    Percent change in body weight

    Zeitrahmen From baseline to week 52

  4. Sekundärer Endpunkt

    Olatorepatide concentrations

    Zeitrahmen Up to approximately 60 weeks

  5. Sekundärer Endpunkt

    Occurrence of Anti-Drug Antibody (ADA) to olatorepatide

    Zeitrahmen Up to approximately 52 weeks

  6. Sekundärer Endpunkt

    Magnitude of ADA to olatorepatide

    Zeitrahmen Up to approximately 52 weeks

Daten

Daten
Startdatum28. Juli 2026 (tatsächlich)
Primärer Abschluss21. Januar 2028 (geschätzt)
Abschluss21. Januar 2028 (geschätzt)
Erstveröffentlichung6. Juli 2026 (tatsächlich)
Zuletzt aktualisiert18. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtNovember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

22 Studienzentren rekrutieren

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Flourish Research, Ravenswood RheumatologyChicagoIllinoisRekrutiert
Charter Research LLC - ChicagoChicagoIllinoisRekrutiert
Alliance for Multispecialty Research (AMR) Clinical MiamiDoralFloridaRekrutiert
AMR Clinical - Fort MyersFort MyersFloridaRekrutiert
Tribe Clinical ResearchGreenvilleSouth CarolinaRekrutiert
AGA Clinical TrialsHialeahFloridaRekrutiert
Flourish Research, Nature Coast Clinical ResearchInvernessFloridaRekrutiert
Flourish Research, Jacksonville Center for Clinical ResearchJacksonvilleFloridaRekrutiert
AMR Clinical - LexingtonLexingtonKentuckyRekrutiert
K2 Medical Research Maitland LLC, Main OfficeMaitlandFloridaRekrutiert
AMR Clinical - MobileMobileAlabamaRekrutiert
NYC Research IncNew YorkNew YorkRekrutiert
AMR Clinical - Chicago Oak BrookOak BrookIllinoisRekrutiert
Velocity Clinical Research - OmahaOmahaNebraskaRekrutiert
Rochester Clinical ResearchRochesterNew YorkRekrutiert
Flourish Research, Legacy Oaks TowerSan AntonioTexasRekrutiert
The IMA Group, IMA Clinical Research St. PetersburgSt. PetersburgFloridaRekrutiert
Charter Research LLC - The VillagesThe VillagesFloridaRekrutiert
Diablo Clinical Research - Flourish ResearchWalnut CreekCaliforniaRekrutiert
Chase Medical ResearchWaterburyConnecticutRekrutiert
AMR Clinical WichitaWichitaKansasRekrutiert
Clinical Site Partners, LLC DBA Flourish ResearchWinter ParkFloridaRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 18. November 2026

    Studienzentrum hinzugefügt

    1 site added (22 total)

    2122

  2. 13. Oktober 2026

    Studienzentrum hinzugefügt

    3 sites added (21 total)

    1821

  3. 29. September 2026

    Studienzentrum hinzugefügt

    13 sites added (18 total)

    518

  4. 20. August 2026

    Status geändert

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  5. 20. August 2026

    Rekrutierung eröffnet

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  6. 20. August 2026

    Studienzentrum hinzugefügt

    5 sites added (5 total)

    05